Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GLPG2737 · ABBV-2737, G1117337

Small molecule · developed by Lakefront Biotherapeutics NV

Phase 2 Most advanced trial (none active)
LKFT Developer
1 Registered trials

What is GLPG2737?

GLPG2737 is an orally administered capsule drug studied in autosomal dominant polycystic kidney disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-2737, G1117337
Drug type
Small molecule
Therapy area
Renal & urology
Developer
Lakefront Biotherapeutics NV (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7MK589F6SC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04578548 Phase 2 Autosomal Dominant Polycystic Kidney Disease Terminated LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autosomal Dominant Polycystic Kidney Disease

More from Lakefront Biotherapeutics NV

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind GLPG2737

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.